SUMMARY, EXPLANATION AND LIMITATIONS:
CD5 is a T-cell associated marker that is also expressed by two B-cell neoplasms, lymphocytic leukemia and mantle cell lymphoma. CD5 antigen is expressed in 95% of thymocytes and 72% of peripheral blood lymphocytes. It has been shown to react with thymic carcinomas but rarely in thyomas. It has also been observed in a subset of intravascular large B-cell lymphomas and marks some anaplastic large cell lymphomas. CD5 has proven very useful in marking mantle cell lymphoma when used in tandem with Cyclin D1, CD10 and CD23. CD5 is postive for mantle cell lymphoma.
Immunogen: Synthetic peptide from the intracellular region of CD5.
Staining pattern: Cell membrane.
Positive control: Tissue sample from tonsil or lymp node.
This antibody is designed for the specific localization of human CD5 using IHC techniques in formalin-fixed, paraffin-embedded tissue sections.
CD5 antigen is expressed on activated T lymphocytes and several T cell leukemias CD5 be included in the panel immunohistochemical study of T lymphoma and is positive in mycosis fungoides and is deleted in the majority of T cell lymphomas anaplastic large (ALK), in lymphomatoid papulosis and blastics lymphomas and NK / T . The CD5 is expressed in the majority of chronic lymphatic leukemia of B origin (LLC) and a feature in mantle cell lymphoma (centrocytic diffuse lymphoma formerly), which together with cyclin D1 positivity can distinguish lymphoma follicular center (FCC) as FCC lymphomas are negative for both markers. In the large cell lymphomas were positive for CD5 recognizes a variant of more aggressive clinical behavior.